How do disease severity and etiology influence the choice between selexipag and parenteral PGI2 analogs for the treatment of pulmonary arterial hypertension?
In real-world Japanese practice, the choice between selexipag and parenteral PGI2 analogs for PAH is driven by disease severity and etiology, with parenteral agents reserved for more severe cases.
Parenteral PGI2 analogs tend to be used mainly in patients with severe IPAH/HPAH, while selexipag is used in patients with a broader range of etiologies around NYHA-FC II-III. Choice of selexipag and parenteral PGI2 analogs for treatment of PAH is influenced by disease severity and etiology.
Tamura et al. (Thu,) studied this question.